[ad_1]
The data on the protective effect are based on the Novavax Phase 3 study in the UK, covering 15,000 people aged 18 to 84. Approximately 27 percent of the participants are over 65 years old. The data is expected to form part of the documentation the company submits when the vaccine is screened for approval in the UK, the EU and other countries, Reuters writes.
According to the company, the vaccine has a protective effect of 89.3% against covid-19. It is said to be almost as effective against the British variant of the virus, which is considered more contagious. The vaccine should provide an 85.6% protective effect against the variant, which circulated during the study.
The vaccine is also indicated It has been shown to provide a 60% protective effect for HIV-negative people in South Africa, where another variant circulates, which is also considered more contagious. This is demonstrated by the large study of 4,400 people of the company in the country, which has reached half.
“The risk of covid-19 disease, which is reduced by 60% in vaccinated people in South Africa, underscores the value of this vaccine in protecting against the disease of the very worrisome variant currently circulating in South Africa, which is spreading widely. global, “says Professor Shabir Maddi, who leads the Novavax South Africa study for Reuters.
Novavax claims that they have begun to manufacture alternative versions of the vaccine that are adapted to the new variants of the virus that have emerged. Clinical trials of the sequelae are scheduled for the second trimester.
The EU is holding on right now and final negotiations with Novavax. According to Sweden’s vaccine coordinator Richard Bergström, a deal is expected to be in place in two to three weeks with approval expected in April, he says in a text message to DN.
The company’s results can be compared with the vaccines from Moderna and Pfizer, which are already approved by the EU and have a protective effect of around 95 percent against covid-19.
The Novavax vaccine is a protein vaccine, in which researchers start from a coronavirus protein, take its genome (all the genes in an organism), and grow the protein in larger quantities. The protein is then given as a vaccine along with an adjuvant, a substance that activates the body’s ability to produce antibodies.
Read more:
Teacher: The vaccine protects against disease, not infection
What the virus genome reveals about the pandemic
